Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Active, not recruiting · Phase 2 · NCT05609578
Conditions: Advanced NSCLC, Metastatic Lung Cancer
At a glance
- Research payments reported, 2025
- $991,218
- U.S. investigators named
- 20
- Sites paid
- 18
- Planned or actual enrollment
- 90
About the trial
- Sponsor
- Mirati Therapeutics Inc.
- Tested
- Adagrasib oral dose of 400 mg twice daily tablets (drug), Pembrolizumab (combination_product), Chemotherapy: Pemetrexed (combination_product), Cisplatin/Carboplatin (combination_product)
- Dates
- Started 2022-11-22; completion 2026-12-01
- Results posted
- Not yet
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
From ClinicalTrials.gov, last updated 2026-06-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Mirati Therapeutics, Inc. reported $991,218 in research payments for this study in 2025 (24 payments).
Products named: Krazati
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Collin Blakely, MD Hematology & Oncology · San Francisco, CA
- David J. Park, M.D. Medical Oncology · Fullerton, CA
- Amol R. Rao, M.D. Hematology & Oncology · Fountain Valley, CA
- Robert M. Jotte, MD Hematology & Oncology · Lone Tree, CO
- Yanyan Lou, MD Hematology & Oncology · Jacksonville, FL
- Kamal Sharma, D.O. Hematology & Oncology · Lakeland, FL
- Jun Zhang, M.D., PH.D. Medical Oncology · Iowa City, IA
- Marina Chiara Garassino, MD Medical Oncology · Chicago, IL
- Daniel B. Costa, M.D. Hematology & Oncology · Boston, MA
- Pasi Antero Janne, MD PHD Medical Oncology · Boston, MA
- Shirish M. Gadgeel, MD Medical Oncology · Detroit, MI
- Yan Ji, M.D, PH.D. Hematology & Oncology · Saint Paul, MN
- Konstantinos Leventakos, M.D. Medical Oncology · Rochester, MN
- Ajeet Gajra, MD Hematology & Oncology · East Syracuse, NY
- Richard M. Zuniga, MD Hematology & Oncology · Babylon, NY
- Nathan A. Pennell, MD PHD Hematology & Oncology · Cleveland, OH
- Kartik Konduri, MD Medical Oncology · Dallas, TX
- Donald A. Richards, MD Medical Oncology · Tyler, TX
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
- Drew C. Murray Medical Oncology · Bellingham, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $161,986
- Mayo Clinic Sports Medicine $148,576
- Us Oncology Res Llc $137,097
- Saint Joseph Health System $126,967
- Healthpartners Institute $91,532
- Peacehealth Saint Joseph Cancer Center $81,332
- Hematology Oncology Associates of Central New York $67,408
- Dana Farber Cancer Institute, Inc $28,902
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $28,536
- Kumc Research Institute, Incorporated $22,385
- Dana Farber Cancer Institute $19,232
- Henry Ford Health Hospital, MI $18,331
- Mayo Clinic $14,930
- Innovative Clinical Research Institute $13,700
- North Shore Hematology/oncology Associates, P C $11,850
- The University of Chicago Kovler Diabetes Center $9,555
- Cleveland Clinic, OH $6,900
- Memorialcare Health System $2,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.